Per Källblad, Ph.D.

Chief Executive Officer

Per Källblad co-founded Beactica in 2006 and is Chief Executive Officer. He has significant international experience in interdisciplinary pharmaceutical research and has worked in collaborations with Aventis, Rhone-Poulenc Rorer, Roche, Cancer Research UK, Peakdale Molecular, Biovitrum and Tibotec.

Per received his Ph.D. in Drug Design from Cambridge University, UK. He was a founding scientist at De Novo Pharmaceuticals Ltd (1999-2004), a Cambridge University spin-off that raised £17.5m in venture capital to bring a new drug discovery tool to market. At Medivir AB he worked with preclinical strategies for therapeutic targets on internal and external projects (2004-2006)

Ulf Bremberg, Ph.D. 

Chief Scientific Officer

Ulf Bremberg joined Beactica as Chief Scientific Officer in 2015. Ulf has a background in medicinal chemistry and significant experience of industrial pharmaceutical research, with emphasis on early discovery, patent strategies and oncology. He has previously headed up the Lead Identification Facility at the Drug Discovery & Development Platform of SciLifeLab, a national pharmaceutical research infrastructure formed by a collaboration between Karolinska Institute, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Earlier positions include Chief Scientific Officer of OncoTargeting AB as well as positions as Chemistry Team Leader and Medicinal Chemist at Biovitrum and Pharmacia. Ulf did his post-doc at the Scripps Research Institute and holds a Ph.D. in Organic Chemistry from KTH Royal Institute of Technology.

Vendela Parrow, Ph.D. 

Head of Preclinical Development

Vendela Parrow joined Beactica as Head of Preclinical Development in 2019. She brings with her an extensive experience in preclinical and clinical development from key positions at Akinion Pharmaceuticals, Axelar and Pharmacia Biovitrum. Vendela was a Co-founder, CSO and CEO of Akinion with responsibility for the interactions with competent authorities, independent review boards and clinics in several European countries. She is Head of Facility of In Vitro and Systems Pharmacology Facility at SciLifeLab Drug Discovery and Development Platform. Vendela received her PhD in Medical Sciences, tumour biology, from Uppsala University where she also passed her exam in Clinical Drug Development.

Jan-Olof Karlsson, B.B.A. 

Chief Financial Officer

Jan-Olof Karlsson joined Beactica as Chief Financial Officer in 2014. He has a diverse and extensive experience of finance and business administration from a wide range of business including Qurit AB, Uppsala Monitoring Center, Karlit AB (formerly part of IKEA), Smedstorp Snickeri AB, Foodfiles AB, Biotage AB, Pharmacia AB. Jan-Olof has a Bachelor of Business Administration from Uppsala University.